Marpai (Marpai) Risk Assessment

View and export this data going back to 2021. Start your Free Trial

What is Marpai Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Marpai is: No Data: Cannot be evaluated.

Competitive Comparison of Marpai's Risk Assessment

For the Healthcare Plans subindustry, Marpai's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Marpai's Risk Assessment Distribution in the Healthcare Plans Industry

For the Healthcare Plans industry and Healthcare sector, Marpai's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Marpai's Risk Assessment falls into.

Marpai (NAS:MRAI) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Marpai Risk Assessment Related Terms

Thank you for viewing the detailed overview of Marpai's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Marpai (Marpai) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Plans » Marpai Inc (NAS:MRAI) » Definitions » Risk Assessment

Comparable Companies

PFHO UNH ELV CI CVS HUM CNC MOH SZSE:000503 ALHC BSP:ODPV3 OSCR CLOV BSP:QUAL3 BHG ROCO:6665 MIL:HI TSXV:NXG

Traded in Other Exchanges

N/A

Address

5701 East Hillsborough Avenue, Suite 1417, Tampa, FL, USA, 33610-5428

Website

https://www.marpaihealth.com

Marpai Inc operates as a health plan company. It uses A.I. to predict and help prevent costly events for its members, and in turn, lower its clients' health care costs. It offers a health plan services system that addresses the problems of healthcare past and enables companies to provide healthcare to employees. The company generates the majority of its revenue from the United States.

Executives

Yaron Eitan	director	65 CHALLENGER ROAD, RIDGEFIELD PARK NJ 07660
Damien Lamendola	director, 10 percent owner	5701 EAST HILLSBOROUGH AVENUE, SUITE 1417, TAMPA FL 33610-5428
Edmundo Gonzalez	director, officer: CEO, Secretary and Director	C/O SELWAY CAPITAL ACQUISITION CORP., 74 GRAND AVENUE, 2ND FLOOR, ENGLEWOOD NJ 07631
Sagiv Shiv	director
Vincent Kane	director	5701 EAST HILLSBOROUGH AVENUE, SUITE 1417, TAMPA FL 33131
Ronnie Brown	officer: Chief Operating Officer	5701 EAST HILLSBOROUGH AVENUE, SUITE 1417, TAMPA FL 33610-5428
Mohsen Moazami	director	C/O ASTREA ACQUISITION CORP., 55 OCEAN LANE DRIVE, APT. 3021, KEY BISCAYNE FL 33149
Lutz Finger	officer: See Remarks	5701 EAST HILLSBOROUGH AVENUE, SUITE 1417, TAMPA FL 33610
Yoram Bibring	officer: Chief Financial Officer	C/O SELWAY ACQUISITION CORPORATION, 66 FORD ROAD, SUITE 230, DENVILLE NJ 07834
Jane Cavalier	director	5701 EAST HILLSBOROUGH AVENUE, SUITE 1417, TAMPA FL 33610-5428
Diclaudio Colleen	director	456 SEATON STREET, LOS ANGELES CA 90013
Art Hoath	officer: Chief Revenue Officer	5701 EAST HILLSBOROUGH AVENUE, SUITE 1417, TAMPA FL 33610-5428
Gonen Antebi	director	5701 EAST HILLSBOROUGH AVENUE, SUITE 1417, TAMPA FL 33610-5428
Eli David	other: See footnote (1)	5701 EAST HILLSBOROUGH AVENUE, SUITE 1417, TAMPA FL 33131